Ipsen sells North American rights to Parkinson's drug to Britannia
This article was originally published in Scrip
Executive Summary
Ipsen has sold to Britannia Pharmaceuticals the development and marketing rights for Apokyn (apomorphine) in North America, where the drug is the only product indicated for the acute, intermittent treatment of hypomobility "off" episodes associated with advanced Parkinson's disease.